Is there a place for neoadjuvant hormonal therapy before radical prostatectomy or radiation therapy in the management of prostate cancer?

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue , 1999, Pages S8-S11

  Teillac, P ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTINENCE; HUMAN; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0033400332     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500319     Document Type: Article

References (13)

1. 0 prostate cancer: a multicentric randomized trial. In: EAU and EUF Symposium, Symposium III: Therapeutic Options for Localized and Locally Advanced Prostate Cancer, 16-17 May 1997, Brussels, p8 (abstract).
2. Teillac P, Lucas C. Maximal androgen blockade before radical prostatectomy versus prostatectomy: a 1 year follow-up in a randomised multicenter prospective study. Eur Urol 1999; 35(Suppl 2): 87 (abstract no. 348).
3. Goldenberg SL, Klotz LH, Jewett MA, Barkin J, Chetner M, Fradet Y, Chin J and the Canadian Uro-Oncology Group. A randomized trial of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy: 24 months post-treatment PSA results. J Urol 1997; 157(part 2): 92 (abstract no. 357).
4. Soloway M, Sharifi R, Wajsman Z, Puras-Baez A. Radical pros-tectomy alone vs radical prostectomy preceded by androgen blockade in cT2b prostate cancer: 24 month results. J Urol 1997; 157(4): 160.
5. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K. Hormonal treatment before radical prostatectomy: a 3-year followup. J Urol 1998; 159(6): 2013-2016 (discussion of 2016-2017).
6. Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Tetu B et al. Downstating of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 1993; 16(6): 499-509.
7. Fair WR, Aprikian A, Sogani P, Reuter V, Whitmore WF Jr. The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 1993; 71(Suppl 3): 1031-1038.
8. Debruyne FM, Witjes WP, Schulman CC, van Cangh PJ, Ooster-hof GO. A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment. Eur Urol 1994; 26(Suppl 1): 4.
9. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995; 154(2, part 1): 424-428.
10. Hugosson J, Abrahamsson PA, Ahlgren G, Aus G, Lundberg S, Schelin S, Schain M, Pedersen K. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost threefold in patients given neo-adjuvant hormone treatment. Eur Urol 1996; 29(4): 413-419.
11. Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin JM, Bullock MJ, Laplante S and the Canadian Urologic Oncology Group. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol 1996; 156(3): 873-877.
12. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45(4): 616-623 (see comments).
13. Zelefsky MJ, Lyass O, Fuks Z, Wolfe T, Burman C, Ling CC, Leibel SA. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 1998; 16(10): 3380-3385.